Shire's Ornskov on $1 Billion Potential for Dry-Eye Drug(Audio)

Bloomberg Intelligence

(Bloomberg) -- Taking Stock with Kathleen Hays and Pimm Fox. GUEST: Shire CEO Flemming Ornskov on the outlook for the company after getting FDA approval for Xiidra drops to treat dry-eye disease.

See omnystudio.com/listener for privacy information.

2016-07-12 8 min Transcript

Available Results

Generated results are saved to your library for reuse and search.

No generated results are available for this episode yet.

Transcript

Open the Transcript tab to load the transcript.

Chapters

No chapters available.